MRX-2843
Phase 1Small molecule
MRX-2843 is one of 12 small molecule programs targeting Relapsed/Refractory AML. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Relapsed/refractory AML
#DrugCompanyPhaseTrials
1Cytosar
TevaApproved
Venclexta
AbbVieApproved
Leustatin
EMD SeronoApproved
Dacogen
Sun Pharmaceutical Industries, Inc.Phase 2
G-CSF
AArog Pharmaceuticals, Inc.
Phase 3
Luye
Ascentage Pharma Group Inc.Phase 2
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Jakafi
IncytePhase 1
Lisaftoclax
Ascentage Pharma Group Inc.Phase 2
MRX-2843
MMeryx, Inc.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MRX-2843. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- MMeryx, Inc.